Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix

Mathumai Kanapathipillai; Akiko Mammoto; Tadanori Mammoto; Joo H. Kang; Elisabeth Jiang; Kaustabh Ghosh; Netanel Korin; Ashley Gibbs; Robert Mannix; Donald E. Ingber

doi:https://doi.org/10.1021/nl301206p

Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix

Mathumai Kanapathipillai, Akiko Mammoto, Tadanori Mammoto, Joo H. Kang, Elisabeth Jiang, Kaustabh Ghosh, Netanel Korin, Ashley Gibbs, Robert Mannix, Donald E. Ingber

Research output: Contribution to journal › Article › peer-review

Abstract

A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.

Original language	English
Pages (from-to)	3213-3217
Number of pages	5
Journal	Nano Letters
Volume	12
Issue number	6
DOIs	https://doi.org/10.1021/nl301206p
State	Published - 13 Jun 2012
Externally published	Yes

Keywords

Cancer
extracellular matrix
lysyl oxidase
mechanics
nanoparticle

All Science Journal Classification (ASJC) codes

General Chemistry
Condensed Matter Physics
Mechanical Engineering
Bioengineering
General Materials Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1021/nl301206p

Cite this

@article{57798b95ae2948458ba48d841e54994f,

title = "Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix",

abstract = "A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.",

keywords = "Cancer, extracellular matrix, lysyl oxidase, mechanics, nanoparticle",

author = "Mathumai Kanapathipillai and Akiko Mammoto and Tadanori Mammoto and Kang, {Joo H.} and Elisabeth Jiang and Kaustabh Ghosh and Netanel Korin and Ashley Gibbs and Robert Mannix and Ingber, {Donald E.}",

year = "2012",

month = jun,

day = "13",

doi = "https://doi.org/10.1021/nl301206p",

language = "الإنجليزيّة",

volume = "12",

pages = "3213--3217",

journal = "Nano Letters",

issn = "1530-6984",

publisher = "American Chemical Society",

number = "6",

}

TY - JOUR

T1 - Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix

AU - Kanapathipillai, Mathumai

AU - Mammoto, Akiko

AU - Mammoto, Tadanori

AU - Kang, Joo H.

AU - Jiang, Elisabeth

AU - Ghosh, Kaustabh

AU - Korin, Netanel

AU - Gibbs, Ashley

AU - Mannix, Robert

AU - Ingber, Donald E.

PY - 2012/6/13

Y1 - 2012/6/13

N2 - A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.

AB - A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.

KW - Cancer

KW - extracellular matrix

KW - lysyl oxidase

KW - mechanics

KW - nanoparticle

UR - http://www.scopus.com/inward/record.url?scp=84862301989&partnerID=8YFLogxK

U2 - https://doi.org/10.1021/nl301206p

DO - https://doi.org/10.1021/nl301206p

M3 - مقالة

SN - 1530-6984

VL - 12

SP - 3213

EP - 3217

JO - Nano Letters

JF - Nano Letters

IS - 6

ER -

Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix

Abstract

Keywords

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this